SEC Info - Goldenberg David M, et al. - ‘SC 13D’ on 10/29/02 re: Immunomedics Inc

SEC Info℠

Home

Help

Please Sign In

Goldenberg David M, et al. – ‘SC 13D’ on 10/29/02 re: Immunomedics Inc

On: Tuesday, 10/29/02, at 5:20pm ET · Accession #: 722830-2-41 · File #: 5-35857

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

10/29/02  Goldenberg David M                SC 13D                 1:20K  Immunomedics Inc                  Immunomedics Inc
          Cynthia L. Sullivan

General Statement of Beneficial Ownership — Schedule 13D
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: SC 13D      Schedule 13 D Oct 2002                                11     39K

Document Table of Contents

Page	(sequential)	\|	(alphabetic)	Top
			Alternative Formats (Word, et al.) Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer Identity and Background Interest in Securities of the Issuer Material to be Filed as Exhibits Purpose of Transaction Schedule 13D Security and Issuer Source and Amount of Funds or Other Consideration
1	1st Page - Filing Submission
"	Schedule 13D
4	Item 1. Security and Issuer
"	Item 2. Identity and Background
5	Item 3. Source and Amount of Funds or Other Consideration
6	Item 4. Purpose of Transaction
"	Item 5. Interest in Securities of the Issuer
8	Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer
"	Item 7. Material to be Filed as Exhibits

SC 13D 1st Page of 11 TOC ↑Top Previous Next ↓Bottom Just 1st
 
 UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

 Under the Securities Exchange Act of 1934

(Amendment No. 7)*

Immunomedics, Inc.
--------------------------------------------------------------------------------
(Name of Issuer)

 Common Stock, $0.01 par value
--------------------------------------------------------------------------------
(Title of Class of Securities)

--------------------------------------------------------------------------------
 452907 10 8
--------------------------------------------------------------------------------
(CUSIP Number)

 Joseph E. Mullaney III, Esquire
 Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
One Financial Center
 Boston, Massachusetts 02111
 (617)542-6000

--------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)

 July 25, 2002
--------------------------------------------------------------------------------
 (Date of Event which Requires Filing of this Statement)

If the filing person has previously  filed a statement on Schedule 13G to report
the  acquisition  that is the subject of this  Schedule  13D, and is filing this
schedule because of ss.ss. 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the
following box.[ ]                                                               

NOTE:  Schedules  filed in paper format shall include a signed original and five
copies of the  schedule,  including all  exhibits.  See ss.  240.13d-7 for other
parties to whom copies are to be sent.                                          

*The  remainder of this cover page shall be filled out for a reporting  person's
initial filing on this form with respect to the subject class of securities, and
for  any  subsequent   amendment   containing   information  which  would  alter
disclosures provided in a prior cover page.                                     

The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the  Securities  Exchange  Act of
1934 ("Act") or otherwise  subject to the liabilities of that section of the Act
but  shall be  subject  to all other  provisions  of the Act  (however,  see the
Notes).                                                                         

Page 1 of 11 pages

SC 13D 2nd Page of 11 TOC 1st Previous Next ↓Bottom Just 2nd
SCHEDULE 13D
=============================                                                   
 13D
CUSIP NO.  452907  10  8                                                        
=============================                                                   

================================================================================
1     NAMES OF REPORTING PERSONS                                              
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)       
Dr. David M. Goldenberg                                           

---- ---------------------------------------------------------------------------
2     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP                (a)[ ]  
    (See Instructions)                                              (b)[ ]
---- ---------------------------------------------------------------------------
3     SEC USE ONLY                                                            
---- ---------------------------------------------------------------------------
4     SOURCE OF FUNDS (See Instructions)                                      
PF/OO                                                             
---- ---------------------------------------------------------------------------
5     CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO    
    ITEMS 2(d) or 2(e)                                                 [ ]
---- ---------------------------------------------------------------------------
6     CITIZENSHIP OR PLACE OF ORGANIZATION                                    
United States                                                     
================================================================================

NUMBER OF                       7   SOLE VOTING POWER                     
SHARES                              4,005,257                             
                                  ---- -----------------------------------------
BENEFICIALLY                    8   SHARED VOTING POWER                   
OWNED BY                            3,856,926                             
                                  ---- -----------------------------------------
EACH                            9   SOLE DISPOSITIVE POWER                
REPORTING                           3,702,428                             
                                  ---- -----------------------------------------
PERSON                         10   SHARED DISPOSITIVE POWER              
WITH                                3,856,926                             
================================================================================

11    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON            
7,862,183                                                         
---- ---------------------------------------------------------------------------

 12    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [ ]

---- ---------------------------------------------------------------------------

13    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)                      
15.5%                                                             
---- ---------------------------------------------------------------------------

14    TYPE OF REPORTING PERSON (See Instructions)                             
IN                                                                
================================================================================

Page 2 of 11 pages

SC 13D 3rd Page of 11 TOC 1st Previous Next ↓Bottom Just 3rd
SCHEDULE 13D
=============================                                                   
 13D
CUSIP NO.  452907  10  8                                                        
=============================                                                   

================================================================================
1     NAMES OF REPORTING PERSONS                                              
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)       
Cynthia L. Sullivan                                               

---- ---------------------------------------------------------------------------
2     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP                (a)[ ]  
    (See Instructions)                                              (b)[ ]
---- ---------------------------------------------------------------------------
3     SEC USE ONLY                                                            
---- ---------------------------------------------------------------------------
4     SOURCE OF FUNDS (See Instructions)                                      
PF/OO                                                             
---- ---------------------------------------------------------------------------
5     CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO    
    ITEMS 2(d) or 2(e)                                                 [ ]
---- ---------------------------------------------------------------------------
6     CITIZENSHIP OR PLACE OF ORGANIZATION                                    
United States                                                     
================================================================================

NUMBER OF                       7   SOLE VOTING POWER                     
SHARES                              245,631                               
                                  ---- -----------------------------------------
BENEFICIALLY                    8   SHARED VOTING POWER                   
OWNED BY                            7,435,585                             
                                  ---- -----------------------------------------
EACH                            9   SOLE DISPOSITIVE POWER                
REPORTING                           245,631                               
                                  ---- -----------------------------------------
PERSON                         10   SHARED DISPOSITIVE POWER              
WITH                                7,435,585                             
================================================================================

11    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON            
7,681,216                                                         
---- ---------------------------------------------------------------------------

 12    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [ ]

---- ---------------------------------------------------------------------------

13    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)                      
15.4%                                                             
---- ---------------------------------------------------------------------------

14    TYPE OF REPORTING PERSON (See Instructions)                             
IN                                                                
================================================================================

Page 3 of 11 pages

SC 13D 4th Page of 11 TOC 1st Previous Next ↓Bottom Just 4th
This  Amendment  No. 7 amends and  restates in its  entirety  the  Schedule  13D
Amendment No. 6 filed on behalf of Dr. David M. Goldenberg on August 24, 2001.  

Item 1. Security and Issuer                                                     

Common Stock, $0.01 par value ("Common Stock")                                  

Immunomedics, Inc., 300 American Road, Morris Plains, New Jersey 07950          

Item 2. Identity and Background                                                 

(a)                                                                             

(i)  Dr. David M. Goldenberg                                          

(ii) Cynthia L. Sullivan                                              

(b)                                                                             

     (i)  c/o Immunomedics,  Inc., 300 American Road, Morris Plains,  New Jersey
07950                                                       

     (ii) c/o Immunomedics,  Inc., 300 American Road, Morris Plains,  New Jersey
07950                                                       

(c)                                                                             

     (i)  Chairman of the Board of  Directors  and Chief  Scientific  Officer of
          Immunomedics,   Inc.,  a  biopharmaceutical  company  focused  on  the
          development,  manufacture  and marketing of monoclonal  antibody-based
          products of the  detection  and  treatment of cancer and other serious
          diseases.  Immunomedics,  Inc. is located at 300 American Road, Morris
          Plains,  New Jersey 07950.  Dr. David M.  Goldenberg is the husband of
Cynthia L. Sullivan.                                        

     (ii) President  and  Chief  Executive  Officer  of  Immunomedics,  Inc.,  a
          biopharmaceutical company focused on the development,  manufacture and
          marketing of monoclonal  antibody-based  products of the detection and
          treatment of cancer and other serious diseases.  Immunomedics, Inc. is
          located at 300 American Road, Morris Plains, New Jersey 07950. Cynthia
L. Sullivan is the wife of Dr. David M. Goldenberg.         

Page 4 of 11 pages  

SC 13D 5th Page of 11 TOC 1st Previous Next ↓Bottom Just 5th
(d)                                                                             

     (i)  During the last five years, Dr. Goldenberg has not been convicted in a
          criminal   proceeding   (excluding   traffic   violations  or  similar
misdemeanors).                                              

     (ii) During the last five years,  Ms.  Sullivan has not been convicted in a
          criminal   proceeding   (excluding   traffic   violations  or  similar
misdemeanors).                                              

(e)                                                                             

     (i)  During the last five years,  Dr.  Goldenberg has not been a party to a
          civil  proceeding  of a judicial or  administrative  body of competent
          jurisdiction and as a result of such proceeding was or is subject to a
          judgment,  decree or final order  enjoining  future  violations of, or
          prohibiting  or  mandating  activities  subject  to,  federal or state
       securities laws or finding any violation with respect to such laws.

     (ii) During the last five  years,  Ms.  Sullivan  has not been a party to a
          civil  proceeding  of a judicial or  administrative  body of competent
          jurisdiction and as a result of such proceeding was or is subject to a
          judgment,  decree or final order  enjoining  future  violations of, or
          prohibiting  or  mandating  activities  subject  to,  federal or state
       securities laws or finding any violation with respect to such laws.

(f)                                                                             

(i)  United States                                                    

(ii) United States                                                    

Item 3. Source and Amount of Funds or Other Consideration                       

     The shares of Common Stock were  originally  acquired  more than five years
prior to the date of this  amended  Schedule 13D (except to the extent that such
shares of Common Stock were subsequently transferred among members of the family
of David M.  Goldenberg  and trusts or entities  controlled by such persons) and
the  source  and  amount  of funds  previously  expended  is thus not  material.
Substantially all of the shares were acquired upon the initial capitalization of
Immunomedics,  Inc.  From time to time  since the  acquisition  of such  shares,
certain of such  shares  have been  transferred  among  members of the family of
David M.  Goldenberg  and trusts or entities  controlled by such  persons.  This
Schedule  13D  amendment  does not reflect any  acquisitions  of Common Stock of
Immunomedics,  Inc. made by Dr. Goldenberg.  Rather,  this amendment is filed to
reflect a change in the direct ownership of shares of Common Stock  beneficially
owned by Dr.  Goldenberg  resulting  from (i) the transfer by Dr.  Goldenberg of
1,500,000  shares of Common Stock to a grantor  retained  annuity  trust for his
benefit, (ii) transfers by Dr. Goldenberg among members of his family and trusts

Page 5 of 11 pages  

SC 13D 6th Page of 11 TOC 1st Previous Next ↓Bottom Just 6th
or entities controlled by such persons,  (iii) the disposition by Dr. Goldenberg
of 34,725  shares of  Common  Stock in  exchange  for an 18.3%  interest  in IBC
Pharmaceuticals,  Inc., a 73% owned subsidiary of  Immunomedics,  Inc., (iv) Dr.
Goldenberg no longer  serving as an officer or director of Escalon  Corporation,
and (v) Dr.  Goldenberg no longer serving as an officer,  director or trustee of
Escalon  Foundation.   This  amendment  also  adds  Cynthia  L.  Sullivan,   Dr.
Goldenberg's wife, as a reporting person on this Schedule 13D.                  

Item 4. Purpose of Transaction                                                  

     Neither Dr.  Goldenberg nor Ms. Sullivan has any present plans or proposals
of the types set forth in paragraphs  (a) through (j) of Item 4 of Schedule 13D.
Dr.  Goldenberg  and Ms.  Sullivan  may, from time to time,  acquire  additional
shares of Common  Stock or  dispose  of all or a portion of the shares of Common
Stock beneficially owned by him or her, as applicable, either in the open market
or in privately  negotiated  transactions.  Dr.  Goldenberg and Ms. Sullivan may
also obtain  additional  shares of Common  Stock upon the  exercise of the stock
options described in Item 5 of Schedule 13D.                                    

Item 5. Interest in Securities of the Issuer                                    

(a)                                                                             

     (i)  As of October 9, 2002, Dr.  Goldenberg  beneficially  owned  7,862,183
          shares of Common Stock,  or 15.5% of the total  outstanding  shares of
Common Stock.                                               

     (ii) As of October 9,  2002,  Ms.  Sullivan  beneficially  owned  7,681,216
          shares of Common Stock,  or 15.4% of the total  outstanding  shares of
Common Stock.                                               

(b)                                                                             

     (i)  With respect to Dr. Goldenberg's beneficial ownership of Common Stock,
          he has sole  voting and  dispositive  power over  3,702,428  shares of
          Common Stock, of which (i) 2,902,428 shares are held by Dr. Goldenberg
          directly,  and (ii) 800,000  shares may be acquired by Dr.  Goldenberg
          upon   exercise  of  options  to  purchase   shares  of  Common  Stock
          exerciseable  within 60 days of the date of this amended Schedule 13D.
          Dr.  Goldenberg also has sole voting power over an additional  302,829
          shares  pursuant to an agreement  with  Hildegard  Gruenbaum Katz (his
          former wife). Dr.  Goldenberg has shared voting and dispositive  power
          over 3,856,926  shares of Common Stock, of which (i) 21,931 shares are
          held by Ms. Sullivan, Dr. Goldenberg's wife, (ii) 3,576,570 shares are
          held by Dr.  Goldenberg  as  beneficial  owner  of the  three  grantor
          retained  annuity trusts dated January 8, 2001, April 3, 2001 and July
          25, 2002, respectively, the trustees of which are Ms. Sullivan, Eva J.
          Goldenberg  and Deborah S.  Orlove,  (iii)  34,725  shares are held by

Page 6 of 11 pages  

SC 13D 7th Page of 11 TOC 1st Previous Next ↓Bottom Just 7th
          Immunomedics, Inc.'s 73% owned subsidiary, IBC Pharmaceuticals,  Inc.,
          a Delaware  corporation  which  focuses on the  development  of cancer
          radiotherapeutics, of which Dr. Goldenberg is the sole director and an
          18.3%  stockholder,  (iv)  11,200  shares Ms.  Sullivan  has voting or
          dispositive  power as  custodian  of her  children or as trustee for a
          trust for their benefit, and (v) 212,500 shares may be acquired by Ms.
          Sullivan upon  exercise of options to purchase  shares of Common Stock
         exerciseable within 60 days of the date of this amended Schedule 13D.

     (ii) With respect to Ms. Sullivan's  beneficial  ownership of Common Stock,
          she has sole  voting  and  dispositive  power over  245,631  shares of
          Common  Stock,  of which (i) 21,931  shares  are held by Ms.  Sullivan
          directly,  (ii) 212,500  shares may be acquired by Ms.  Sullivan  upon
          exercise of options to purchase  shares of Common  Stock  exerciseable
          within 60 days of the date of this  amended  Schedule  13D,  and (iii)
          11,200  shares  Ms.  Sullivan  has  voting  or  dispositive  power  as
          custodian of her children or as trustee for a trust for their benefit.
          Ms.  Sullivan has shared voting and  dispositive  power over 7,435,585
          shares of Common Stock, of which (i) 2,902,428  shares are held by Dr.
          Goldenberg,  Ms.  Sullivan's  husband,  (ii)  800,000  shares  may  be
          acquired by Dr. Goldenberg upon exercise of options to purchase shares
          of  Common  Stock  exerciseable  within  60 days  of the  date of this
          amended  Schedule 13D, (iii) 3,576,570 shares are held as a trustee of
          three  grantor   retained  annuity  trusts  for  the  benefit  of  Dr.
          Goldenberg  dated  January 8, 2001,  April 3, 2001 and July 25,  2002,
          respectively, the trustees of which also include Eva J. Goldenberg and
          Deborah S. Orlove, (iv) 34,725 shares are held by Immunomedics, Inc.'s
          73% owned subsidiary, IBC Pharmaceuticals, Inc., of which Ms. Sullivan
          is  president,  and (v) 121,862  shares are held as trustee of Escalon
          Foundation,  a not-for-profit  corporation organized under the laws of
          the State of New Jersey,  the  trustees  of which also  include Eva J.
Goldenberg and Deborah S. Orlove.                           

(c)                                                                             

     (i)  Dr.  Goldenberg  did not effect any  transactions  in the Common Stock
during the past sixty days.                                 

     (ii) Ms.  Sullivan  did not effect  any  transactions  in the Common  Stock
during the past sixty days.                                 

(d)                                                                             

     (i)  No  other  person  is  known to Dr.  Goldenberg  to have the  right to
          receive or the power to direct the receipt of dividends  from,  or the
          proceeds  from the sale of,  the shares of Common  Stock  beneficially
owned by him, except as disclosed in Item 5(b)(i).          

Page 7 of 11 pages  

SC 13D 8th Page of 11 TOC 1st Previous Next ↓Bottom Just 8th
     (ii) No other person is known to Ms.  Sullivan to have the right to receive
          or the power to direct the receipt of dividends  from, or the proceeds
          from the sale of, the  shares of Common  Stock  beneficially  owned by
him, except as disclosed in Item 5(b)(ii).                  

(e)                                                                             

(i)  Not applicable.                                                  

(ii) Not applicable.                                                  

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to
Securities of the Issuer                                                        

     Dr.  Goldenberg has an agreement with Hildegard  Gruenbaum Katz (his former
wife) to vote 302,829 shares of Common Stock owned by her.            

Item 7. Material to be Filed as Exhibits                                        

        Exhibit 1*  Agreement,  dated as of February 10, 1997, between Hildegard
                    Gruenbaum  and David M.  Goldenberg,  regarding  the  voting
                    power of 302,829 shares of Common Stock was previously filed
                    as Exhibit  2.E to  Schedule  13D  Amendment  No. 4 filed on
                    March  6,  1997 and is  incorporated  by  reference  to this
amendment.                              

        Exhibit 2** Joint  Filing  Agreement,  dated  as of  October  29,  2002,
            between David M. Goldenberg and Cynthia L. Sullivan.

*  Previously filed                                           
** Filed herewith                                             

Page 8 of 11 pages  

SC 13D 9th Page of 11 TOC 1st Previous Next ↓Bottom Just 9th
 SIGNATURE

     After reasonable inquiry and to the best of the knowledge and belief of the
undersigned, each of the undersigned certifies that the information set forth in
this statement is true, complete and correct.                                   

Date: October 29, 2002                               /s/  David M. Goldenberg   
                                                  ------------------------
                                             David M. Goldenberg

Date: October 29, 2002                               /s/  Cynthia L. Sullivan   
                                                  ------------------------
                                             Cynthia L. Sullivan

Page 9 of 11 pages  

SC 13D 10th Page of 11 TOC 1st Previous Next ↓Bottom Just 10th
                                                                     Exhibit 2

JOINT FILING AGREEMENT

     Each  of the  undersigned  represents  that  he or she is  eligible  to use
Schedule 13D to report his or her beneficial ownership (as defined in Rule 13d-3
promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange
Act"))  of  common  stock,  par  value  $.01  per  share  ("Common  Stock"),  of
Immunomedics, Inc., a Delaware corporation ("Immunomedics").                    

Each of the undersigned agrees:                                       

1.   that he or she is responsible  for the timely filing of a Schedule 13D, and
     any  amendments  thereto (the "Schedule  13D"),  with respect to his or her
     beneficial  ownership  reporting  obligations  with  respect  to the Common
Stock;                                                                

2.   that he or she is  responsible  for the  completeness  and  accuracy of the
     information concerning him or her contained in the Schedule 13D, but is not
     responsible for the completeness or accuracy of the information  concerning
     the other person making the filing, unless he or she knows or has reason to
believe that such information is inaccurate; and                      

3.   in accordance with Rule 13d-1(k)(1)  promulgated under the Exchange Act, to
     the  joint  filing  with the  other  person  executing  this  joint  filing
     agreement  (this  "Agreement"),  on behalf of each of them, of the Schedule
     13D (including all amendments  thereto) and that this Agreement be included
as an exhibit to the Schedule 13D.                                    

     This Agreement may be executed in any number of counterparts, each of which
shall be  deemed to be an  original,  but all of which,  taken  together,  shall
constitute one and the same instrument.                                         

[Remainder of page intentionally left blank]

Page 10 of 11 pages 

SC 13D Last Page of 11 TOC 1st Previous Next ↓Bottom Just 11th
     IN WITNESS WHEREOF, the undersigned have caused this Agreement to be signed
as of October 29, 2002.                                                         

                                        /s/  David M. Goldenberg
                                        ------------------------
                                   David M. Goldenberg

                                        /s/  Cynthia L. Sullivan
                                        ------------------------
                                   Cynthia L. Sullivan

Page 11 of 11 pages

SC 13D	1st Page of 11	TOC	↑Top	Previous	Next	↓Bottom	Just 1st

SC 13D	2nd Page of 11	TOC	1st	Previous	Next	↓Bottom	Just 2nd

SC 13D	3rd Page of 11	TOC	1st	Previous	Next	↓Bottom	Just 3rd

SC 13D	4th Page of 11	TOC	1st	Previous	Next	↓Bottom	Just 4th

SC 13D	5th Page of 11	TOC	1st	Previous	Next	↓Bottom	Just 5th

SC 13D	6th Page of 11	TOC	1st	Previous	Next	↓Bottom	Just 6th

SC 13D	7th Page of 11	TOC	1st	Previous	Next	↓Bottom	Just 7th

SC 13D	8th Page of 11	TOC	1st	Previous	Next	↓Bottom	Just 8th

SC 13D	9th Page of 11	TOC	1st	Previous	Next	↓Bottom	Just 9th

SC 13D	10th Page of 11	TOC	1st	Previous	Next	↓Bottom	Just 10th

SC 13D	Last Page of 11	TOC	1st	Previous	Next	↓Bottom	Just 11th

Dates Referenced Herein and Documents Incorporated by Reference

		Referenced-On Page
This ‘SC 13D’ Filing	Date	First	Last	Other Filings

Filed on:	10/29/02	8	11	SC 13G
	10/9/02	6
	7/25/02	1	7
	8/24/01	4		SC 13D/A
	4/3/01	6	7
	1/8/01	6	7
	3/6/97	8		SC 13D
	2/10/97	8
				List all Filings

↑Top

Filing Submission 0000722830-02-000041 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Goldenberg David M, et al. – ‘SC 13D’ on 10/29/02 re: Immunomedics Inc

On: Tuesday, 10/29/02, at 5:20pm ET · Accession #: 722830-2-41 · File #: 5-35857

Previous ‘SC 13D’: ‘SC 13D/A’ on 8/24/01 · Next & Latest: ‘SC 13D/A’ on 9/25/08

General Statement of Beneficial Ownership — Schedule 13DFiling Table of Contents

Document Table of Contents

Dates Referenced Herein and Documents Incorporated by Reference

General Statement of Beneficial Ownership — Schedule 13D
Filing Table of Contents